02.06.2014 \/ 09:00 <\/p>\n
--------------------------------------------------------------------- <\/p>\n
Berlin, Germany and Nevada, USA, June 2, 2014 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, today announced that it will participate in the dbAccess German, Swiss & Austrian Conference 2014 held by Deutsche Bank from June 11 until June 13, 2014, in Berlin, Germany. <\/p>\n
Meeting Details: <\/p>\n
Speaker: Dr. Ben J. Lipps Date of presentation: Friday, June 13, 2014; 08:00 am CET Location: Hotel Adlon Kempinski, Unter den Linden 77, 10117 Berlin Availability for 1-on-1-meetings: Wednesday, June 11, 2014; 12:30 - 18:30 CET & Friday, June 13, 2014; all day <\/p>\n
The presentation will be also made available on Magforce's website on http:\/\/www.magforce.com<\/a>. <\/p>\n About MagForce AG <\/p>\n MagForce AG, listed in the entry standard (MF6), together with its subsidiary MAGFORCE USA, Inc. is a leading medical device company in the field of nanomedicine in oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit http:\/\/www.magforce.com<\/a>. <\/p>\n Disclaimer <\/p>\n This release may contain forward-looking statements and information which may be identified by formulations using terms such as \"expects\", \"aims\", \"anticipates\", \"intends\", \"plans\", \"believes\", \"seeks\", \"estimates\" or \"will\". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. <\/p>\n <\/p>\n Read more from the original source: 02.06.2014 \/ 09:00 --------------------------------------------------------------------- Berlin, Germany and Nevada, USA, June 2, 2014 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6), a leading medical device company in the field of nanomedicine focused on oncology, today announced that it will participate in the dbAccess German, Swiss & Austrian Conference 2014 held by Deutsche Bank from June 11 until June 13, 2014, in Berlin, Germany. Meeting Details: Speaker: Dr Continue reading
\nDGAP-News: MagForce AG: MagForce AG to present at dbAccess German, Swiss & Austrian Conference 2014, held by Deutsche ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"